DENND2A

Across TCGA pan-cancer cohorts, DENND2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DENND2A data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DENND2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DENND2A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, UCEC, and GBM are the cancer types where DENND2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.848	0.937	.003	17	view →
UCEC	DFS	Tertile	III,IV	0.409	1.000	.016	16	view →
GBM	DFS	Tertile	All	0.223	0.477	.032	4	view →
PDAC	OS	Median	All	0.234	0.999	.049	4	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DENND2A–LUAD (DFS)

Open the LUAD breakdown →